Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
Status:
Not yet recruiting
Trial end date:
2028-08-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomised, multicenter, no placebo-controlled, open label study for
evaluating the efficacy and safety of pyrotinib in women with residual invasive HER2-positive
breast cancer after neoadjuvant chemotherapy plus anti-HER2 target therapy. The main purpose
is to investigate whether pyrotinib can further reduce the risk of recurrence from previously
diagnosed HER-2 positive breast cancer based on the 1-year trastuzumab standard adjuvant
treatment with or without pertuzumab.